PFE · 10-Q · 2026Q2 · Full report

Patent Exclusivity Expiries

PFIZER INC · 2026-08-04 · Importance 58 · Surprise 42

Pfizer expects a significant reduction in revenue from patent-based or regulatory exclusivity expiries as several in-line products lose exclusivity between 2026 and 2030. Management expects the rate of revenue reduction to accelerate significantly over the next few years. For 2026, Pfizer now estimates an unfavorable revenue impact of approximately $1.1 billion.

Key facts

• Given anticipated unfavorable impact from patent-based or regulatory exclusivity expiries, Pfizer expects leverage to remain around current levels, or modestly higher, through this transition period. source
• Pfizer discloses risks that patent applications may not be granted timely or at all, which could affect patent-term extensions and exclusivity. source